Showing 1981-1990 of 2652 results for "".
- Orbis International Appoints Kathleen Sherwin as New President and CEOhttps://modernod.com/news/orbis-international-appoints-kathleen-sherwin-as-new-president-and-ceo/2485326/Global nonprofit organization Orbis International has named Kathleen Sherwin as its new President and Chief Executive Officer, effective immediately. Ms. Sherwin arrives at Orbis with more than 25 years of leadership experience
- Everest Medicines Expands into Ophthalmology with Licensing Agreement for Retinal Disease Candidate in Asiahttps://modernod.com/news/everest-medicines-expands-into-ophthalmology-with-licensing-agreement-for-retinal-disease-candidate-in-asia/2484302/Everest Medicines announced it has entered into an exclusive licensing agreement with Visara, a subsidiary of NovaBridge Biosciences to develop, manufacture, and commercialize VIS-101 in Greater China, Singapore, South Korea, and select Southeast Asian countri
- OneSight EssilorLuxottica Foundation and Vision To Learn Extend Partnership to Expand Vision Care for Children Nationwidehttps://modernod.com/news/onesight-essilorluxottica-foundation-and-vision-to-learn-extend-partnership-to-expand-vision-care-for-children-nationwide/2484209/The OneSight EssilorLuxottica Foundation and Vision To Learn announced a 2-year extension of their 8-year partnership dedicated to providing vision care services to children in need—helping them see clearly and reach their full potential in school and be
- Holland Foundation for Sight Restoration Launches 'Light After Darkness' Fundraising Campaignhttps://modernod.com/news/holland-foundation-for-sight-restoration-launches-light-after-darkness-fundraising-campaign/2484205/The Holland Foundation for Sight Restoration announced the launch of its five-year, $5 million “Light After Darkness” fundraising campaign. The initiative aims to expand access to life-restoring treatment for individua
- Artificial Intelligence-Guided Glaucoma Screening Shows Promisehttps://modernod.com/news/artificial-intelligence-guided-glaucoma-screening-shows-promise/2484195/While artificial intelligence (AI) has already proven effective in screening for diabetic retinopathy, applying similar technology to glaucoma has been more complex. Unlike diabetic retinopathy, glaucoma is not a single disease but a group of conditions characteriz
- Optos Launches Silverstone RGB Retinal Imaging Technologyhttps://modernod.com/news/optos-launches-silverstone-rgb-retinal-imaging-technology/2484187/Optos announced the launch of Silverstone RGB. Building on its flagship Silverstone platform, the new system is designed to deliver a suite of nine imaging modalities in a single device, establishing a new benchmark in retinal imaging technology.
- Johnson & Johnson Marks 100,000 US Implants of Tecnis Odyssey IOL; Showcases Innovations at AAO 2025https://modernod.com/news/johnson-johnson-marks-100000-us-implants-of-tecnis-odyssey-iol-and-showcases-innovations-at-aao-2025/2484177/Johnson & Johnson announced that its Tecnis Odyssey IOL has now been implanted in 100,000 eyes since its 2024 launch. The company will highlight this milestone alongside new data presentations and technology showcases
- BVI Receives FDA Approval for Finevision HP Trifocal IOLhttps://modernod.com/news/bvi-receives-fda-approval-for-finevision-hp-trifocal-iol/2484174/BVI announced that the FDA has approved its Finevision HP trifocal IOL. According to BVI, Finevision HP was the world’s first trifocal IOL, with more than 15 years of clinical success a
- EyeDura Therapeutics Partners with SERI to Advance Insulin-Based Topical Therapy for Neurotrophic Keratitishttps://modernod.com/news/eyedura-therapeutics-partners-with-seri-to-advance-insulin-based-topical-therapy-for-neurotrophic-keratitis/2484157/EyeDura Therapeutics has initiated preclinical efficacy studies in collaboration with the Singapore Eye Research Institute (SERI). The studies will advance the company’s lead insulin-based eye drop treatment for neurotrophic keratitis (NK), a rare, degen
- NICE Approves First NHS Treatment for Leber Hereditary Optic Neuropathy (LHON)https://modernod.com/news/nice-approves-first-nhs-treatment-for-leber-hereditary-optic-neuropathy-lhon/2484140/The UK-based National Institute for Health and Care Excellence (NICE) has approved idebenone (Raxone; Chiesi Pharmaceuticals) for the treatment of Leber Hereditary Optic Neuropathy (LHON) in patients aged 12 years and older. This marks the first time NICE has